Diabetes News and Research

Latest Diabetes News and Research

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.

29 Mar 2012

Ember adds Joslin's BMP7 technology to brown fat intellectual property portfolio

Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the completion of an agreement with the Joslin Diabetes Center to exclusively license intellectual property covering bone morphogenetic protein 7 (BMP7), which has been shown to play a role in the regulation of brown fat development.

29 Mar 2012

Daiichi Sankyo, NGM to discover and develop new treatments for diabetes

Daiichi Sankyo Company, Ltd. and NGM Biopharmaceuticals, Inc. announced today that they have entered into a research collaboration and license agreement to discover and develop novel therapeutics that modulate beta-cell regeneration for the treatment of diabetes.

29 Mar 2012

New McMaster centre to track health differences by ethnicity

Tracking health differences by ethnicity is the cornerstone of the new Chanchlani Research Centre at McMaster University.

29 Mar 2012

Biochemists determine atomic structure of new ABC transporter

Proteins belonging to the large and important family of ABC transporters have been associated with metabolic diseases and can cause resistance to antibiotics. Biochemists from the University of Zurich and the NCCR Structural Biology have succeeded in determining the atomic structure of a new ABC transporter. The insights gained could give rise to new therapies to treat multi-resistant bacteria, cystic fibrosis or gout, for instance.

29 Mar 2012

JDRF, iCo Therapeutics partner for iCo-007 Phase II trial in DME

iCo Therapeutics, a Vancouver-based drug reprofiling company and JDRF, the largest charitable funder of type 1 Diabetes (T1D) research have joined forces to investigate a potential new treatment for one of the most common complications of diabetes, diabetic macular edema.

29 Mar 2012

Ember, Joslin aims to utilize brown fat for treatment of obesity and diabetes

Joslin Diabetes Center and Ember Therapeutics, Inc. today announced an agreement aimed at utilizing "brown fat," a type of fat that helps increase energy expenditure within the body, as a novel technique for managing obesity and diabetes. Joslin's Chief Academic Officer, Dr. Ronald Kahn and other Joslin faculty, Drs. Yu-Hua Tseng and Aaron Cypess, have performed pioneering work in this field over the past several years, and were the first to show that a natural protein called BMP7 can help modulate the levels of brown fat.

29 Mar 2012

Roche announces increase in offer price for outstanding Illumina shares

Roche announced today that it has increased its offer price for all outstanding publicly-held shares of Illumina, Inc. to US$ 51.00 per share in cash.

From Illumina, Inc. 29 Mar 2012

Bariatric surgery may eliminate need for diabetes medication

Diabetes has become an epidemic in the United States, with the number of cases tripling over the last three decades. Most of those cases are Type 2 diabetes, which is linked to obesity and can lead to serious medical issues that range from heart disease to renal failure, blindness, and more.

29 Mar 2012

Researchers describe unexpected role of p75NTR in type 2 diabetes

Scientists at the Gladstone Institutes have discovered a key protein that regulates insulin resistance-the diminished ability of cells to respond to the action of insulin and which sets the stage for the development of the most common form of diabetes. This breakthrough points to a new way to potentially treat or forestall type 2 diabetes, a rapidly growing global health problem.

29 Mar 2012

EU's Safety Evaluation Ultimately Replacing Animal Testing initiative tests Roche's xCELLigence system

Roche's xCELLigence RTCA System is being used in the European Union's SEURAT (Safety Evaluation Ultimately Replacing Animal Testing) initiative to run five years from 2011 to 2016.

From Roche Sequencing and Life Science 29 Mar 2012

Interleukin, U-M School of Dentistry complete enrollment in PST Genetic Test study

The University of Michigan School of Dentistry and Interleukin Genetics, Inc. announced today the completion of patient enrollment for a landmark clinical study using Interleukin's PST Genetic Test to determine if dental patients can be risk-stratified to guide frequency of preventive dental visits and reduce the adverse outcomes of periodontal disease progression, such as tooth loss.

29 Mar 2012

MiR-375 regulates IL-13-induced changes in allergic diseases

Researchers have taken a critical step in understanding how allergic reactions occur after identifying a genetic signature for regulation of a key immune hormone, interleukin (IL-13).

29 Mar 2012

Spherix 2011 net loss decreases to $3.5 million

Spherix Incorporated – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today reported financial results for the year ended December 31, 2011, and recent and upcoming business highlights.

29 Mar 2012

Study sheds light on the impact that zero-calorie beverages may have on health

Are diet sodas good or bad for you? The jury is still out, but a new study sheds light on the impact that zero-calorie beverages may have on health, especially in the context of a person's overall dietary habits.

29 Mar 2012

Scientists uncover new layer of information in the genetic code

A hidden and never before recognized layer of information in the genetic code has been uncovered by a team of scientists at the University of California, San Francisco (UCSF) thanks to a technique developed at UCSF called ribosome profiling, which enables the measurement of gene activity inside living cells - including the speed with which proteins are made.

29 Mar 2012

Losing weight and increasing physical activity reduces decline in mobility in obese adults with type 2 diabetes

Weight loss and increased physical fitness nearly halved the decline in mobility in overweight or obese adults with type 2 diabetes, according to four-year results of the Look AHEAD (Action for Health in Diabetes) trial funded by the National Institutes of Health.

29 Mar 2012